孟鲁司特钠对小儿喘息性支气管炎的临床治疗效果观察  

Clinical effect of montelukast sodium on asthmatic bronchitis in children

作　　者：马野艳 MA Ye-yan(Suizhong County Hospital,Huludao 125200,China)

机构地区：[1]辽宁省葫芦岛市绥中县医院,125200

出　　处：《中国实用医药》2021年第6期13-15,共3页China Practical Medicine

摘　　要：目的观察孟鲁司特钠对小儿喘息性支气管炎的临床治疗效果。方法68例喘息性支气管炎患儿,随机分为对照组及观察组,各34例。对照组患儿采用常规治疗,观察组患儿在对照组的基础上采用孟鲁司特钠治疗。比较两组患儿治疗效果、症状缓解时间、不良反应发生情况及治疗前后炎性指标[白三烯E4(LTE4)、嗜酸性粒细胞阳离子蛋白(ECP)、白细胞介素-10(IL-10)]。结果观察组患儿治疗总有效率97.1%高于对照组的82.4%,差异有统计学意义(P<0.05)。观察组患儿气喘缓解时间(3.3±0.8)d、湿啰音缓解时间(2.7±1.1)d、咳嗽缓解时间(5.2±2.3)d、哮鸣音缓解时间(3.2±0.8)d均短于对照组的(3.9±1.1)、(3.8±1.3)、(6.8±2.0)、(4.1±1.2)d,差异有统计学意义(P<0.05)。治疗后,观察组患儿LTE4(38.58±1.32)pg/L、ECP(9.48±1.01)μg/L、IL-10(9.18±1.02)pg/L均低于对照组的(79.59±1.31)pg/L、(15.44±1.02)μg/L、(13.98±1.03)pg/L,差异有统计学意义(P<0.05)。两组患儿不良反应发生率比较差异无统计学意义(P>0.05)。结论将孟鲁司特钠应用于小儿喘息性支气管炎治疗中可提升患儿治疗效果,缩短临床症状缓解时间,改善患儿炎性指标,值得临床推广应用。Objective To observe the clinical effect of montelukast sodium on asthmatic bronchitis in children.Methods A total of 68 children with asthmatic bronchitis were randomly divided into control group and observation group,with 34 cases in each group.The control group received conventional therapy,and the observation group received montelukast sodium based on the control group.The total effective rate of treatment,symptom remission time,occurrence of adverse reactions,inflammatory indexes[leukotriene E4(LTE4),eosinophil cationic protein(ECP),interleukin-10(IL-10)]before and after treatment were compared between the two groups.Results The total effective rate of treatment 97.1%of the observation group was higher than 82.4%of the control group,and the difference was statistically significant(P<0.05).The asthma remission time(3.3±0.8)d,moist rales remission time(2.7±1.1)d,cough remission time(5.2±2.3)d,and wheezing remission time(3.2±0.8)d of the observation group were shorter than(3.9±1.1),(3.8±1.3),(6.8±2.0)and(4.1±1.2)d of the control group,and the difference was statistically significant(P<0.05).After treatment,the LTE4(38.58±1.32)pg/L,ECP(9.48±1.01)μg/L and IL-10(9.18±1.02)pg/L of the observation group were all lower than(79.59±1.31)pg/L,(15.44±1.02)μg/L and(13.98±1.03)pg/L of the control group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in incidence of adverse reactions between the two groups(P>0.05).Conclusion Montelukast sodium can improve the therapeutic effect of children with athmatic bronchitis,which can shorten the remission time of clinical symptoms and improve the inflammatory index.It is worthy of clinical promotion and application.

关 键 词：孟鲁司特钠 小儿喘息性支气管炎 湿啰音缓解时间 白三烯E4 

分 类 号：R725.6[医药卫生—儿科]